State of Alaska Department of Revenue Sells 135 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

State of Alaska Department of Revenue trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,764 shares of the medical research company’s stock after selling 135 shares during the period. State of Alaska Department of Revenue’s holdings in Charles River Laboratories International were worth $2,909,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Wellington Management Group LLP boosted its stake in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after buying an additional 509,163 shares during the last quarter. Mizuho Securities USA LLC boosted its position in shares of Charles River Laboratories International by 2,336.4% in the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock valued at $19,081,000 after acquiring an additional 92,895 shares during the period. Premier Fund Managers Ltd increased its position in Charles River Laboratories International by 56.3% during the third quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock worth $49,573,000 after acquiring an additional 90,000 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after purchasing an additional 85,759 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Down 1.6 %

Shares of NYSE:CRL opened at $163.65 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $8.37 billion, a P/E ratio of 20.48, a P/E/G ratio of 6.47 and a beta of 1.37. Charles River Laboratories International, Inc. has a 12 month low of $159.65 and a 12 month high of $275.00. The company’s 50-day moving average price is $180.61 and its two-hundred day moving average price is $193.23.

Analyst Ratings Changes

Several analysts have issued reports on the stock. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. TD Cowen lifted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. The Goldman Sachs Group cut their price target on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Redburn Atlantic initiated coverage on Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective on the stock. Finally, StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $200.79.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).